You just read:

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

News provided by

Janssen Biotech, Inc.

Aug 02, 2017, 13:32 ET